Stocks and Investing Stocks and Investing
Mon, November 9, 2020
Fri, November 6, 2020

Martin Auster Maintained (SRPT) at Hold with Decreased Target to $162 on, Nov 6th, 2020


Published on 2024-10-27 14:41:38 - WOPRAI, Martin Auster
  Print publication without navigation


Martin Auster of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Decreased Target from $167 to $162 on, Nov 6th, 2020.

Martin has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 0 agree with Martin's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Martin


  • Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $212 on, Wednesday, October 28th, 2020
  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $190 on, Tuesday, September 15th, 2020
  • Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $221 on, Monday, August 31st, 2020
  • Danielle Brill of "Raymond James" Initiated at Buy and Held Target at $200 on, Tuesday, August 25th, 2020
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $182 on, Monday, August 10th, 2020
Contributing Sources